Parameter
| Biomarker | Cathepsin K | Full name | Serum cysteine protease K | Molecular Type | protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | bone resorption monitoring | ||
| Disease | Osteoporosis (OP) | Disease Subtypes | / | ||
| Organ | Bone | Test Sample / Technology Platform | Serum (ELISA、LC-MS/MS) | ||
| Pathobiological Mechanisms | Osteoclast-specific proteases degrade type I collagen and non-collagenous proteins in the bone matrix, with elevated levels in elderly patients due to excessive osteoclast activation. | ||||
| Clinical Availability Status | Clinical trials in progress | ||||
| Notes and Dynamics | Positively correlated with bone resorption rate, it can predict the risk of vertebral fractures in elderly patients; a ≥50% reduction in cathepsin K inhibitor (e.g., odanacatib) levels post-treatment indicates significant therapeutic efficacy. | ||||